DBCG 2020 - MASTER STUDY

	DDEAT				
DANISH	BREAT	CANCER	COOPER	AIIVE	GROUP

INCLUSION FORM (IN- AND EXCLUSION CRITERIA)

CPR nr:	Name:	Hospital, department					
Patients are only eligible for randomization if all boxes are checked in the marked column. Inclusion Criteria (must be answered "Yes") Women with primary, estrogen receptor positive breast cancer who are candidates for (neo)adjuvant systemic therapy OR have received \$3 years of adjuvant endocrine therapy. Age > 18 years. Yes No Performance status of ECOG \$ 2. Yes No Prior to patient registration, written informed consent must be given according to I Yes No Picis to patient registration, written informed consent must be given according to I Yes No Picis to patient registration, written informed consent must be given according to I Yes No Picis to patient registration, written informed consent must be given according to I Yes No Picor to patient registration, written informed consent must be given according to I Yes No Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 No Yes Inhilitory of Any mode contralateral) invasive breast cancinne level No Yes Predisposing factors or hadomyolysis, including hypotyphyrolism, reduced renail function, any muscle - or liver disease, or excessive alcohol consumption abovel 1 drinks/wek AND creditie, clobaporin or danazol. No Yes Predisposing factors for hadomyolysis, including hypotyphyrolism, reduced renail function, any muscle - or liver disease, or excessive alcoho	CPR nr:						
Inclusion Criteria (must be answered "Yes") Women with primary, estrogen receptor positive breast cancer who are candidates for (neo)adjuvant systemic therapy OR have received ≤3 years of adjuvant endocrine therapy. No Age > 18 years. Yes No Performance status of ECOG ≤ 2. Yes No Prior to patient registration, written informed consent must be given according to IC/KGCP, and national/local regulations. Yes No Exclusion Criteria (must be answered "No") Image: Section and the answered "No") Image: Section Se	•						
Women with primary, estrogen receptor positive breast cancer who are candidates for (neo)adjuvant systemic therapy OR have received ≤ 3 years of adjuvant endocrine therapy. No Age > 18 years. Yes No Performance status of ECOG ≤ 2. Yes No Prior to patient registration, written informed consent must be given according to IYes No Exclusion Criteria (must be answered "No") I History of any prior (ipsi- and/or contralateral) invasive breast carcinoma No Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 No Infiliment of other in- and exclusion criteria. No Evidence of hepatic dysfunction (calanine aminotransferase level more than three times the upper limit of the normal range). No Yes Predisposing factors for rhadomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 1 d' drinks/wee AND creatine kinase (CK) measured to more than five times the upper limit of the normal range). No Yes Predisposing factors for rhadomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 1 d' drinks/wee AND creatine kinase (CK) measured to more than five times the upper limit of the gorgaphical collocal noutines for premonpaus, fertile breast cancer patients, that includes non-hormonal controcation with potent CYBAA+inhibtors (e.g. ketokonazole, erythromycin) or gemibrozile, iclosporin or dana							
Age > 18 years. Yes No Performance status of ECOG ≤ 2. Yes No Prior to patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations. No Yes No Exclusion Criteria (must be answered "No") No Yes No Yes History of any prior (ipsi- and/or contralateral) invasive breast carcinoma No Yes Inhibitors). These patients can be enrolled in the observational cohort given fulfilment of other in- and exclusion criteria. No Yes Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range). No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 14 drinks/week AND creatine kinase (CK) measured to more than five times the upper limit (CK only measured in case of predisposing factors). No Yes Current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or gentificatile, choosing factors). No Yes Pregionacy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm or intraveline device). No Yes Psychological, familial, sociological or geographical conditio	Women with primary, estrogen receptor positive b candidates for (neo)adjuvant systemic therapy OR		Yes	🗌 No			
Performance status of ECOG ≤ 2. Prior to patient registration, written informed consent must be given according to No Prior to patient registration, written informed consent must be given according to Yes No Exclusion Criteria (must be answered "No") Image: Status of ECOS No Yes History of any prior (ipsi- and/or contralateral) invasive breast carcinoma No Yes Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 No Yes fulfilment of other in- and exclusion criteria. No Yes Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range). No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle – or liver disease, or excessive alcohol consumption above 14 drinks/week AND creatine kinase (CK) measured to more than five times the upper limit of CK only measured in case of predisposing factors). No Yes Urrent medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or genfibrozile, ciclosporin or danazol. No Yes Prevhological, familia, sociological or georaphical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes Strata ¹ : Neadyurant entry Adjuva				□ No			
ICH/GCP, and national/local regulations. Ites Ites Ites Ites Exclusion Criteria (must be answered "No") Ites Ites Ites Ites History of any prior (lpsi- and/or contralateral) invasive breast carcinoma No Yes Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 No Yes Inhibitors). These patients can be enrolled in the observational cohort given No Yes Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle – or liver disease, or excessive alcohol consumption above No Yes 14 drinks/week AND creatine kinase (CK) measured to more than five times the upper limit (CK only measured in case of predisposing factors). No Yes Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes				No			
History of any prior (ipsi- and/or contralateral) invasive breast carcinoma No Yes Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 No Yes Inhibitors). These patients can be enrolled in the observational cohort given No Yes Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle – or liver disease, or excessive alcohol consumption above 14 drinks/week AND creatine kinase (CK) measured to case of predisposing factors). No Yes Current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or genfibrozile, ciclosporin or danazol. No Yes Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contomy up contomy the tost up protectile. No Yes contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering composition to atorvastatin. No Yes Strata'': Neoadjuvant entry Adjuvant early entry Adjuvant late entry No Yes Conditions will be discussed with the patient before registrat		Yes	No				
Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 Imbibitors). These patients can be enrolled in the observational cohort given No Yes fulfilment of other in- and exclusion criteria. No Yes Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range). No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 14 dinks/week AND creatine kinase (CK) measured to more than five times the upper limit (OK only measured in case of predisposing factors). No Yes Current medication with potent CYPAAinhibitors (e.g. ketokonazole, erythromycin) or gemfibrozile, ciclosporin or danazol. No Yes Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes Ibiory of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin. No Yes Observational cohort - non randomized patients: Observational cohort - non-randomized patient	Exclusion Criteria (must be answered "No")						
inhibitors). These patients can be enrolled in the observational cohort given INO Yes fulfilment of other in- and exclusion criteria. INO Yes Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range). No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 14 drinks/week AND creatine kinase (CK) measured to more than five times the upper limit (CK only measured in case of predisposing factors). No Yes Current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromyolin) or gemfbrozile, ciclosporin or danazol. No Yes Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry ³ Early stratum: Randomisation <u>before</u> start of (neo)adjuvent therapy. Late stratum: Randomisation <u>after</u> start of adjuvant therapy, but within three years of initiation af endocrine therapy	History of any prior (ipsi- and/or contralateral) invasive breast carcinoma			□ ^{Yes}			
times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range). No Yes Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 14 drinks/week AND creatine kinase (CK) measured to more than five times the upper limit (CK only measured in case of predisposing factors). No Yes Current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or gemfibrozile, ciclosporin or danazol. No Yes Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes Strata ¹): Neoadjuvant entry Adjuvant late entry	inhibitors). These patients can be enrolled in the o	🗌 No	🗌 Yes				
Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption above 14 drinkS/week AND creatine kinase (CK) measured to more than five times the upper limit (CK only measured in case of predisposing factors). No Yes Current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or gemfbrozile, ciclosporin or danazol. No Yes Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry No Yes Observational cohort - non randomized patients: Observational cohort - non randomized patients: No Yes No Yes Observational cohort: non-randomized cohort of patients already on cholesterollowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterollowering medication, fibrates, ezetimike, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. No Yes No	times the upper limit of the normal range) or rena	🗌 No	🗌 Yes				
erythromycin) or gemfibrozile, ciclosporin or danazol. INO INO INO Pregnancy or breast-feeding (contraception according to clinical routines for premenopausal, fertile breast cancer patients, that includes non-hormonal contraception such as condom, vaginal diaphragm, or intrauterine device). No Yes Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. No Yes History of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin. No Yes Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry Imo 1 ¹ Early stratum: Randomisation <u>after</u> start of adjuvant therapy. but within three years of initiation af endocrine therapy Observational cohort - non randomized patients: Observational cohort - non randomized patients Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol-lowering medication criteria can be included in the observational cohort. No Date of informed consent: Filled in by: Name: (CAPITAL LETTERS) Sign: Date: Date: Date: Date: <	Predisposing factors for rhabdomyolysis, including function, any muscle – or liver disease, or excession 14 drinks/week AND creatine kinase (CK) measured upper limit (CK only measured in case of predispos	🗌 No	Yes				
premenopausal, fertile breast cancer patients, that includes non-hormonal No Yes contraception such as condom, vaginal diaphragm, or intrauterine device). Psychological, familial, sociological or geographical condition potentially No Yes Psychological, familial, sociological or geographical condition potentially No Yes hampering compliance with the study protocol and follow-up schedule; these No Yes conditions will be discussed with the patient before registration in the trial. No Yes biological composition to atorvastatin. Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry 1 ¹ Early stratum: Randomisation <u>after</u> start of adjuvant therapy, but within three years of initiation af endocrine therapy Observational cohort - non randomized patients: Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. No Date i Date: Date: Date: Date: MD: Date: Dat		🗌 No	Yes				
hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. History of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin. Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry ') Early stratum: Randomisation before start of (neo)adjuvent therapy. Late stratum: Randomisation after start of adjuvant therapy, but within three years of initiation af endocrine therapy Observational cohort - non randomized patients: Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. Date of informed consent: Patient:	premenopausal, fertile breast cancer patients, that	🗌 No	Pres				
biological composition to atorvastatin. Strata ¹ : Neoadjuvant entry Adjuvant early entry Adjuvant late entry Strata¹: Neoadjuvant entry Adjuvant early entry Adjuvant late entry Adjuvant late entry Adjuvant entry Adjuvant therapy. Late stratum: Randomisation <u>after</u> start of adjuvant therapy, but within three years of initiation af endocrine therapy Observational cohort – non randomized patients: Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise Patient: Patient: Patient: Patient: Patient: Date: CAPITAL LETTERS Sign: CAPITAL LETTERS Sign: Date: Dat	hampering compliance with the study protocol and conditions will be discussed with the patient before	🗌 No	🗌 Yes				
1) Early stratum: Randomisation before start of (neo)adjuvent therapy. Late stratum: Randomisation after start of adjuvant therapy, but within three years of initiation af endocrine therapy Observational cohort - non randomized patients: Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. Date of informed consent: Filled in by: Patient: Name: MD: CAPITAL LETTERS) Sign: Date: dd mm yyyy Date:	History of allergic reactions attributed to compounds of similar chemical or			Yes			
1) Early stratum: Randomisation before start of (neo)adjuvent therapy. Late stratum: Randomisation after start of adjuvant therapy, but within three years of initiation af endocrine therapy Observational cohort - non randomized patients: Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. Date of informed consent: Filled in by: Patient: Name: MD: CAPITAL LETTERS) Sign: Date: dd mm yyyy Date:							
Observational cohort: non-randomized cohort of patients already on cholesterol-lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. Image: Previous Prevalent cholesterol Prevalent cholesterol Prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. Image: Prevalent cholesterol Prevalent	 ¹⁾ Early stratum: Randomisation <u>before</u> start of (neo)adjuvent therapy. Late stratum: Randomisation <u>after</u> start of adjuvant therapy, but within three years of initiation af 						
lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise fulfill in-and exclusion criteria can be included in the observational cohort. Date of informed consent: Patient: MD: Randomized: Date: dd mm yyyy Randomization no :	Observational cohort – non randomized patients:						
Patient: Name: (CAPITAL LETTERS) MD: Date: Sign: Date:	lowering medication at time of diagnosis. Patients that are not able to participate in the randomized placebo-controlled part of the trial due to prevalent cholesterol lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), but otherwise						
MD:Sign:Sign:Sign:Sign:	Date of informed consent:	Filled in by:					
Randomized: Date: Image: Date: Date: Image: Date: Date		Name:(CAPITAL LETTER	Name: (CAPITAL LETTERS)				
Randomized: Date: dd mm yyyy Date:	MD:						
Randomization no '							
		dd mm yyyy					